Comparative Efficacy and Safety of Novel Oral Anticoagulants in Atrial Fibrillation with Chronic Kidney Disease: A Systematic Review, Meta-Regression, and Network Meta-Analysis
Systematic review reveals apixaban's effectiveness and safety in patients with atrial fibrillation and chronic kidney disease, suggesting tailored treatment choices.
Key Points
Apixaban demonstrated the lowest risk of all-cause mortality and stroke/systemic embolism, establishing its superiority.
The analysis incorporated 29 trials with over 187,000 participants, confirming the robustness of the findings.
A systematic review and network meta-analysis evaluated treatment efficacy and highlighted the challenges in managing patients with AF and CKD.
The results indicate a need for more data on newer options like asundexian, especially in advanced chronic kidney disease cases.